Nichole Tucker

Sunvozertinib shows a similar safety profile to other EGFR tyrosine kinase inhibitors in the treatment of EGFR wild-type non–small cell lung cancer in the WO-KONH6 study.

Common treatment-emergent adverse effects among patients receiving PRT811 for uveal melanoma or advanced glioma include nausea and vomiting in a phase 1 study.

Findings from the phase 3 BREAKWATER study indicate that encorafenib plus cetuximab and chemotherapy produces activity and is well-tolerated in metastatic colorectal cancer harboring BRAF V600E mutations.

Patients with with primary central nervous system lymphoma experienced prolonged progression-free survival and a reduction in risk of death following treatment with high-dose chemotherapy and autologous stem cell transplant compared with non-myeloablative chemoimmunotherapy.

A triple-class exposed population of patients diagnosed with relapsed or refractory multiple myeloma experienced progression-free survival benefit following treatment with belantamab mafodotin with pomalidomide and dexamethasone.

The phase RIGHT Choice trial yield a 46% reduction in disease progression when ribociclib was added to endocrine therapy for patients with pre/perimenopausal hormone-receptor–positive/HER2-negative advanced breast cancer.

Findings from the phase 3 DREAMseq trial indicated that the best course of treatment for individuals diagnosed with advanced BRAF-mutated melanoma is first-line nivolumab/ipilimumab, with BRAF/MEK inhibitors used in later-line settings.

Benefits of larotrectinib in patients with tumors harboring NTRK fusions have been established, with new data showing health-related quality of life benefits with its use.

An analysis presented at 2022 ASCO reveals a potential correlation between CDKN2A/B as well as cell cycle pathway alterations and brain metastases in non–small cell lung cancer.

Patients with TRK fusion–positive central nervous system tumors were observed to have increased efficacy and safety when treated with larotrectinib at long-term follow-up.

Chances of reaching complete remission and minimal residual disease negativity were greater with the addition of inotuzumab to hyper-CVAD with sequential blinatumomab in patients with Philadelphia chromosome–negative B-cell acute lymphoblastic lymphoma.

Three year follow-up findings from a post hoc analysis of the phase 3 ARAMIS trial indicated that darolutamide maintained a survival benefit regardless of prior local therapy for patients with nonmetastatic castration-resistant prostate cancer.

Patients with high-risk large B-cell lymphoma experienced potent, long-term responses following treatment with axicabtagene ciloleucel in the first line.

The CoVac-1 vaccine appears to reduce COVID-19 symptoms for patients with cancer who have disease- or treatment-related immunoglobulin deficiency.

Adjuvant durvalumab combined with different monoclonal antibodies led to enriched major pathologic responses in early-stage non–small cell lung cancer.

Data from the TITAN-RCC trial presented at 2022 ASCO GU showed that certain immune cell–related parameters may be predictive of response to nivolumab/ipilimumab in advanced or metastatic clear cell renal cell carcinoma

Patients with KRAS-mutant metastatic colorectal cancer who were treated with a combination containing onvansertib had a tolerable safety profile.

A post hoc analysis showed that a dose reduction of selinexor yielded higher safety and efficacy for patients with multiple myeloma.

Weekly selinexor combined with bortezomib and dexamethasone appears to be a promising option in patients with high-risk multiple myeloma.

The combination of trastuzumab deruxtecan and pertuzumab could improve efficacy over trastuzumab deruxtecan alone for patients with HER2-positive metastatic breast cancer.

A select group of patients with metastatic renal cell carcinoma may benefit from cytoreductive nephrectomy followed by active surveillance as an alternative option to systemic therapy.

Results of the phase 2 SAKK 08/16 trial indicate a benefit to switching to darolutamide maintenance following prior therapies for metastatic castration-resistant prostate cancer.

Some improvement in pathological complete response may be possible with SD-101 plus pembrolizumab and paclitaxel in certain patients with HER2-negative breast cancer, but results are still uncertain.

When performed with a reduced-intensity conditioning regimen of bortezomib, fludarabine, and melphalan, alloHCT was safe in patients with high-risk multiple myeloma.

Adding parsaclisib to the ruxolitinib treatment of patients with myelofibrosis who had a suboptimal response on a standard dose of ruxolitinib alone led to improvements in spleen volume reduction and symptom burden.

The androgen receptor inhibitor enzalutamide, an approved therapy for certain types of prostate cancer, has shown activity for the treatment of patients with recurrent or advanced endometrioid endometrial cancer.

PFS improvement as well as a trend to overall survival prolongation has been demonstrated with niraparib maintenance in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations.

“Preliminary TRIDENT-1 data are very encouraging and support repotrectinib as a potential best-in-class treatment in ROS1-positive advanced NSCLC,” according to Byoung Chul Cho, MD, PhD.

Statistically significant improvements in PFS were seen with the multitarget kinase inhibitor anlotinib in Chinese patients with refractory metastatic colorectal cancer, with OS differences noted in certain subgroups.

Treatment with the oral agent showed sustained health-related quality of life compared with placebo in patients with acute myeloid leukemia, according to results of the phase 3 QUAZAR AML-001 trial.